Therapeutic drug monitoring of voriconazole after intravenous administration in infants and children with primary immunodeficiency.
A voriconazole trough concentration (Ctrough) <1 mg/L is associated with a higher risk of treatment failure. The aim of this work was to describe the probability of not achieving this target concentration in infants and children receiving intravenous voriconazole. Voriconazole trough concentrations obtained during routine therapeutic drug monitoring over a 5-year period were collected retrospectively from infants and children receiving intravenous voriconazole for presumed or proven invasive fungal infections. Sixty-two trough concentrations were obtained from 6 infants and 10 children. The risk of a Ctrough <1 mg/L was 77% and 47%, respectively. Daily doses between 20 and 32 mg/kg were necessary in some patients to achieve a Ctrough >1 mg/L, compared with the currently recommended 14-mg/kg regimen. Routine therapeutic drug monitoring is potentially helpful in infants and children receiving voriconazole, even intravenously.